Combination therapy for inflammatory bowel disease

doi:10.4292/wjgpt.v8.i2.103

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9863)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

1035

WORD

510

HTML

5473

Tables (1-2)

263

Sum=7281

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1094

Download

1488

Sum=2582

May 6, 2017 (publication date) through Nov 24, 2024

Times Cited of This Article

Times Cited (24)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastrointest Pharmacol Ther. May 6, 2017; 8(2): 103-113
Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.103

Table 1 Author’s summary of the evidence for combination therapy

	Crohn’s disease		Ulcerative colitis
	Clinical benefit	Pharmacokinetic/immunogenic benefit	Clinical benefit	Pharmacokinetic/immunogenic benefit
IFX + AZA/6MP (treatment naïve)	+	+	+	+
IFX + AZA/6MP (step-up from immunomodulator monotherapy)	-	NA	NA	NA
IFX + MTX	+/-	+	NA	NA
ADA + IMM	+/-	+/-	NA	NA
VDZ + IMM	NA	+	NA	NA
Ustekinumab +	NA	NA	NA	NA
IMM	NA	NA	NA	NA

IFX: Infliximab; AZA: Azathioprine; 6-MP: 6-mercaptopurine; MTX: Methotrexate; ADA: Adalimumab; VDZ: Vedolizumab; IMM: immunomodulatory; +: beneficial; +/-: Possible benefit; NA: No adequate data available.

Citation: Sultan KS, Berkowitz JC, Khan S. Combination therapy for inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2017; 8(2): 103-113
URL: https://www.wjgnet.com/2150-5349/full/v8/i2/103.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v8.i2.103